DelveInsight's 'Non-Small-Cell Lung Carcinoma (NSCLC) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Non-Small-Cell Lung Carcinoma (NSCLC) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Study Period: 2017-2030
The DelveInsight Non-Small-Cell Lung Carcinoma (NSCLC) epidemiology report gives a thorough understanding of the Non-Small-Cell Lung Carcinoma (NSCLC) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Non-Small-Cell Lung Carcinoma (NSCLC) in the US, Europe, and Japan. The report covers the detailed information of the Non-Small-Cell Lung Carcinoma (NSCLC) epidemiology scenario in seven major countries (US, EU5, and Japan).
The Non-Small-Cell Lung Carcinoma (NSCLC) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Non-Small-Cell Lung Carcinoma (NSCLC) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Non-Small-Cell Lung Carcinoma (NSCLC) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
The Non-Small-Cell Lung Carcinoma (NSCLC) epidemiology covered in the report provides historical as well as forecasted Non-Small-Cell Lung Carcinoma (NSCLC) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
The DelveInsight Non-Small-Cell Lung Carcinoma (NSCLC) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
1. Key Insights
2. Executive Summary of Non-Small-Cell Lung Carcinoma (NSCLC)
3. Non-Small-Cell Lung Carcinoma (NSCLC): Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
5.5.2.1. Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
5.5.3.1. Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
5.5.4.1. Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Non-Small-Cell Lung Carcinoma (NSCLC) Treatment and Management
6.2. Non-Small-Cell Lung Carcinoma (NSCLC) Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
*The table of contents is not exhaustive; will be provided in the final report
Table 1 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in 7MM (2017-2030)
Table 2 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in 7MM (2017-2030)
Table 3 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in the United States (2017-2030)
Table 4 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in the United States (2017-2030)
Table 5 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in Germany (2017-2030)
Table 6 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in Germany (2017-2030)
Table 7 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in France (2017-2030)
Table 8 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in France (2017-2030)
Table 9 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in Italy (2017-2030)
Table 10 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in Italy (2017-2030)
Table 11 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in Spain (2017-2030)
Table 12 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in Spain (2017-2030)
Table 13 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in the United Kingdom (2017-2030)
Table 14 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Table 15 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in Japan (2017-2030)
Table 16 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in Japan (2017-2030)
Figure 1 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in 7MM (2017-2030)
Figure 2 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in 7MM (2017-2030)
Figure 3 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in the United States (2017-2030)
Figure 4 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in the United States (2017-2030)
Figure 5 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in Germany (2017-2030)
Figure 6 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in Germany (2017-2030)
Figure 7 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in France (2017-2030)
Figure 8 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in France (2017-2030)
Figure 9 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in Italy (2017-2030)
Figure 10 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in Italy (2017-2030)
Figure 11 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in Spain (2017-2030)
Figure 12 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in Spain (2017-2030)
Figure 13 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in the United Kingdom (2017-2030)
Figure 14 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Figure 15 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in Japan (2017-2030)
Figure 16 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in Japan (2017-2030)
*The table of contents is not exhaustive; will be provided in the final report